📣 VC round data is live. Check it out!

Passage Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Passage Bio and similar public comparables like Jupiter Neurosciences, Alligator Bioscience, NFL Biosciences, Pharma Equity Group and more.

Passage Bio Overview

About Passage Bio

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.


Founded

2017

HQ

United States

Employees

60

Financials (LTM)

Revenue:
Net Income: ($43M)

Market Cap

$15M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Passage Bio Financials

Passage Bio reported last 12-month revenue of —.

In the same LTM period, Passage Bio generated — in gross profit and had net loss of ($43M).

Revenue (LTM)


Passage Bio P&L

In the most recent fiscal year, Passage Bio reported revenue of and EBITDA of ($42M).

Passage Bio is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.

See analyst estimates for Passage Bio
LTMLast FY202320242025202620272028
EBITDA($42M)($99M)($62M)($42M)
Net Profit($43M)($46M)($102M)($65M)($46M)

Financial data powered by Morningstar, Inc.

Passage Bio Stock Performance

Passage Bio has current market cap of $15M.

Market Cap Evolution


Passage Bio's stock price is $4.61.

Passage Bio share price decreased by 9.7% in the last 30 days, and by 47.1% in the last year.

Passage Bio has an EPS (earnings per share) of $-14.19.

See more trading valuation data for Passage Bio
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$15M-7.2%-9.7%-49.0%-47.1%$-14.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Passage Bio Valuation Multiples

Passage Bio trades at 0.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Passage Bio

Passage Bio Financial Valuation Multiples

As of May 5, 2026, Passage Bio has market cap of $15M.

Passage Bio has a P/E ratio of (0.3x).

LTMLast FY202320242025202620272028
EV/EBITDA0.2x0.1x0.1x0.2x
EV/EBIT0.2x0.2x0.1x0.1x0.2x
P/E(0.3x)(0.3x)(0.1x)(0.2x)(0.3x)
EV/FCF0.2x0.1x0.2x0.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Passage Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Passage Bio Margins & Growth Rates

See estimated margins and future growth rates for Passage Bio

Passage Bio Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth(37%)(32%)
EBIT Growth(37%)(34%)
Net Profit Growth(37%)(30%)
FCF Growth(39%)(34%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Passage Bio Operational KPIs

Passage Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Access forward-looking KPIs for Passage Bio
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.7M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Passage Bio Competitors

Passage Bio competitors include Jupiter Neurosciences, Alligator Bioscience, NFL Biosciences, Pharma Equity Group, Argenica Therapeutics, Poxel, Abera Bioscience, Diamyd Medical, NextCell Pharma and Celyad Oncology.

Most Passage Bio public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Jupiter Neurosciences741.0x(1.9x)
Alligator Bioscience222.0x(22.3x)(1.3x)
NFL Biosciences(3.0x)(2.9x)
Pharma Equity Group(4.5x)
Argenica Therapeutics0.7x0.9x
Poxel3.9x(2.1x)
Abera Bioscience(12.1x)
Diamyd Medical364.3x(0.3x)(0.3x)

This data is available for Pro users. Sign up to see all Passage Bio competitors and their valuation data.

Start Free Trial

Passage Bio Funding History

Before going public, Passage Bio raised $226M in total equity funding, across 2 rounds.


Passage Bio Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-19Series BAccess Biotechnology; Boxer Capital; Frazier Healthcare Partners; Highline Capital Management; Lilly Asia Ventures; Logos Capital; New Leaf Venture Partners; OrbiMed; Sphera Funds Management; Versant Ventures; Vivo Capital$110MPassage Bio, a genetic medicines company based in Philadelphia, develops AAV-delivered gene therapies for rare monogenic central nervous system (CNS) diseases, including GM1 gangliosidosis, frontotemporal dementia (FTD), and Krabbe disease. The company was spun out from the University of Pennsylvania's Gene Therapy Program (GTP) and Orphan Disease Center, with GTP handling IND-enabling preclinical work while Passage Bio manages clinical development, regulatory affairs, manufacturing, and commercialization. It launched in February 2019 with a $115.5 million Series A financing led by OrbiMed, followed by the $110 million Series B on September 4, 2019, led by Access Biotechnology with participation from existing investors OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lilly Asia Ventures, New Leaf Venture Partners, Vivo Capital, and new investors Boxer Capital, Highline Capital Management, Logos Capital, and Sphera Funds Management. Total funding raised since inception through December 31, 2019, reached $225.5 million. Proceeds from the Series B supported advancement of its lead programs into clinical trials, with plans to initiate phase 1/2 trials for GM1 gangliosidosis (PBGM01) and FTD (PBFT02) in the first half of 2020, and Krabbe disease (PBKR03) in the second half, though timelines later shifted. Passage Bio had licensed five programs from Penn with options for seven more, plus discovery-stage assets targeting metachromatic leukodystrophy, ALS subsets, and Charcot-Marie-Tooth disease. At year-end 2019, cash reserves stood at $158.9 million. The company progressed to a $216 million IPO in February 2020 (upsized to $248 million with over-allotment), listing on Nasdaq as PASG at $18 per share to fund clinical trials and pipeline expansion. Liam Ratcliffe of Access Biotechnology joined the board upon Series B close. Passage Bio ended 2019 with strong investor backing reflective of confidence in its team and Penn collaboration.
Feb-19Series AFrazier Healthcare Partners; Lilly Asia Ventures; New Leaf Venture Partners; OrbiMed; Versant Ventures; Vivo Capital$116MPassage Bio launched on February 14, 2019, with a $115.5 million Series A financing led by OrbiMed and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital, and Lilly Asia Ventures. The funding supports development of AAV-delivered therapeutics for rare monogenic CNS diseases through a research collaboration and license agreement with the University of Pennsylvania's Gene Therapy Program (GTP) and Orphan Disease Center (ODC). GTP handles IND-enabling preclinical work, while Passage Bio manages clinical development, regulatory affairs, manufacturing, and commercialization; ODC focuses on natural history studies, KOL engagement, and patient advocacy. Lead programs target GM1 gangliosidosis and frontotemporal dementia (FTD), with plans to advance into clinical trials. Passage Bio also holds options for up to seven additional rare monogenic CNS programs from Penn GTP. The company was co-founded by gene therapy veterans James Wilson, Ph.D., from Penn GTP, and Hirofumi Yamada, Ph.D., former head of Novartis Gene Therapies. Board members include Carl Gordon from OrbiMed, Patrick Heron from Frazier Healthcare Partners, and Tom Woiwode from Versant Ventures. Seven months later, Passage Bio raised $110 million in a Series B led by Access Biotechnology, bringing total funding to $225.5 million. The company later pursued an IPO in 2020 and initiated clinical trials for its lead programs, though timelines shifted.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Passage Bio

When was Passage Bio founded?Passage Bio was founded in 2017.
Where is Passage Bio headquartered?Passage Bio is headquartered in United States.
How many employees does Passage Bio have?As of today, Passage Bio has over 60 employees.
Who is the CEO of Passage Bio?Passage Bio's CEO is William Chou.
Is Passage Bio publicly listed?Yes, Passage Bio is a public company listed on Nasdaq.
What is the stock symbol of Passage Bio?Passage Bio trades under PASG ticker.
When did Passage Bio go public?Passage Bio went public in 2020.
Who are competitors of Passage Bio?Passage Bio main competitors include Jupiter Neurosciences, Alligator Bioscience, NFL Biosciences, Pharma Equity Group, Argenica Therapeutics, Poxel, Abera Bioscience, Diamyd Medical, NextCell Pharma, Celyad Oncology.
What is the current market cap of Passage Bio?Passage Bio's current market cap is $15M.
Is Passage Bio profitable?No, Passage Bio is not profitable.
What is the current net income of Passage Bio?Passage Bio's last 12 months net income is ($43M).
How many companies Passage Bio has acquired to date?Passage Bio hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Passage Bio has invested to date?Passage Bio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Passage Bio

Lists including Passage Bio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial